NASDAQ : VRTX
Vertex Pharmaceuticals Incorporated — Key statistics
Healthcare · Biotechnology · United States
Last price 558.88 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 141.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 141.85B |
| Enterprise Value | 130.19B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 253.46M |
| Shares Outstanding | 253.46M |
| Shares Change (YoY) | -0.85% |
| Shares Change (QoQ) | -0.43% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 96.88% |
| Float | 252.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 32.57 |
| Forward PE | 29.11 |
| PS Ratio | 11.36 |
| Forward PS | 10.21 |
| PB Ratio | 6.99 |
| P/TBV Ratio | 7.63 |
| P/FCF Ratio | 37.66 |
| P/OCF Ratio | 33.30 |
| PEG Ratio | 2.31 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 29.80 |
| EV / Sales | 10.43 |
| EV / EBITDA | 25.74 |
| EV / EBIT | 26.74 |
| EV / FCF | 34.58 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.19 |
| Quick Ratio | 2.54 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 0.52 |
| Interest Coverage | 369.14 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 23.54% |
| Return on Assets (ROA) | 11.93% |
| Return on Invested Capital (ROIC) | 28.80% |
| Return on Capital Employed (ROCE) | 20.90% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | $1.97M |
| Profits Per Employee | $688,313 |
| Employee Count | 6,400 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.47 |
Taxes
| Measure | Value |
|---|
| Income Tax | 869.30M |
| Effective Tax Rate | 16.48% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +32.34% |
| 50-Day Moving Average | 523.52 |
| 200-Day Moving Average | 479.84 |
| Relative Strength Index (RSI) | 68.88 |
| Average Volume (20 Days) | 1,383,369 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.26M |
| Short Previous Month | 4.50M |
| Short % of Shares Out | 1.68% |
| Short % of Float | 1.69% |
| Short Ratio (days to cover) | 3.66 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 12.59B |
| Gross Profit | 6.92B |
| Operating Income | 4.91B |
| Pretax Income | 5.27B |
| Net Income | 4.41B |
| EBITDA | 5.10B |
| EBIT | 4.91B |
| Earnings Per Share (EPS) | $17.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.85B |
| Total Debt | 1.98B |
| Net Cash | 11.66B |
| Net Cash Per Share | $46.02 |
| Equity (Book Value) | 20.25B |
| Book Value Per Share | 79.92 |
| Working Capital | 8.61B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 4.29B |
| Capital Expenditures | -496.80M |
| Depreciation & Amortization | 190.90M |
| Net Borrowing | -5.40M |
| Free Cash Flow | 3.80B |
| FCF Per Share | $14.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | 54.96% |
| Operating Margin | 39.00% |
| Pretax Margin | 41.90% |
| Profit Margin | 35.00% |
| EBITDA Margin | 40.52% |
| EBIT Margin | 39.00% |
| FCF Margin | 30.16% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.85% |
| Shareholder Yield | 0.85% |
| Earnings Yield | 3.07% |
| FCF Yield | 2.66% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $571.46 |
| Price Target Difference | 2.11% |
| Analyst Consensus | Buy |
| Analyst Count | 32 |
| Revenue Growth Forecast (3Y) | 11.35% |
| EPS Growth Forecast (3Y) | 9.75% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 24, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 11.58 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |